XML 88 R73.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregates of Total Net Product Revenues from External Customers by Product (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue from External Customer [Line Items]      
Revenue $ 2,096,039 $ 1,846,275 $ 1,860,455 [1]
Total net product revenues      
Revenue from External Customer [Line Items]      
Revenue 2,042,025 1,783,498 1,805,861 [1]
VIMIZIM | Marketed by Company      
Revenue from External Customer [Line Items]      
Revenue 663,739 623,145 544,257
NAGLAZYME | Marketed by Company      
Revenue from External Customer [Line Items]      
Revenue 443,794 380,449 391,298
PALYNZIQ | Marketed by Company      
Revenue from External Customer [Line Items]      
Revenue 255,032 237,474 170,983
KUVAN | Marketed by Company      
Revenue from External Customer [Line Items]      
Revenue 227,577 285,776 457,736
VOXZOGO | Marketed by Company      
Revenue from External Customer [Line Items]      
Revenue 169,128 5,855 0
BRINEURA | Marketed by Company      
Revenue from External Customer [Line Items]      
Revenue 154,333 128,034 110,192
FIRDAPSE | Marketed by Company      
Revenue from External Customer [Line Items]      
Revenue 0 0 1,288
Total net product revenues marketed by the Company | Marketed by Company      
Revenue from External Customer [Line Items]      
Revenue 1,913,603 1,660,733 1,675,754
ALDURAZYME net product revenues marketed by Sanofi | Marketed by Sanofi      
Revenue from External Customer [Line Items]      
Revenue 128,422 122,765 130,107
Royalty and other revenues      
Revenue from External Customer [Line Items]      
Revenue $ 54,014 $ 62,777 $ 54,594 [1]
[1] Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.